KNIGHT THERAPEUTICS news, videos and press releases
For more news please use our advanced search feature.
KNIGHT THERAPEUTICS - More news...
KNIGHT THERAPEUTICS - More news...
- Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
- Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
- Knight Therapeutics Inc. Celebrates its First Decade of Success
- Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
- Knight Therapeutics Reports Third Quarter 2023 Results
- Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
- Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
- Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
- Knight Announces Normal Course Issuer Bid
- Knight Therapeutics Inc. announces voting results from the Annual General Meeting
- Knight to Present at the 2023 RBC Capital Markets Global Healthcare Conference in New York City
- Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call
- Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
- Knight Therapeutics Inc. ranks on The Globe and Mail’s fourth-annual Women Lead Here benchmark of executive gender diversity
- Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results
- Knight Therapeutics Closes US$38.5 million Loan with IFC
- Knight Therapeutics Reports Second Quarter 2022 Results
- Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference
- Knight to Present at the 2022 BIO International Convention in San Diego
- Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia
- Knight Therapeutics Inc. announces voting results from the Annual Meeting
- Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call
- Knight Announces Normal Course Issuer Bid
- Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon® in Canada and Latin America
- Knight Therapeutics Reports First Quarter 2021 Results
- Knight Therapeutics Announces Leadership Change
- Knight Therapeutics to Acquire Regional Rights to Exelon®
- Knight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference
- Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results
- Knight Announces Filing of Final Base Shelf Prospectus